Oak Associates Ltd. OH Decreases Stake in Jazz Pharmaceuticals PLC $JAZZ

Oak Associates Ltd. OH cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,772 shares of the specialty pharmaceutical company’s stock after selling 2,969 shares during the period. Oak Associates Ltd. OH’s holdings in Jazz Pharmaceuticals were worth $3,549,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in JAZZ. Royal Bank of Canada grew its holdings in shares of Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares in the last quarter. Focus Partners Wealth lifted its position in Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after purchasing an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, Director Heather Ann Mcsharry sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares in the company, valued at $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares of the company’s stock, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,098 shares of company stock worth $3,131,906 over the last ninety days. 4.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research reports. Canaccord Genuity Group began coverage on shares of Jazz Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $290.00 target price on the stock. Robert W. Baird set a $252.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Needham & Company LLC boosted their price objective on Jazz Pharmaceuticals from $255.00 to $282.00 and gave the stock a “buy” rating in a research note on Monday. Piper Sandler upped their price objective on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, May 22nd. Finally, Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $259.06.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $254.87 on Friday. The business has a fifty day moving average of $236.87 and a 200 day moving average of $202.88. The stock has a market cap of $16.01 billion, a P/E ratio of -12,737.13, a PEG ratio of 0.22 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $255.20.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.